Review
Copyright ©2014 Baishideng Publishing Group Inc.
World J Immunol. Jul 27, 2014; 4(2): 88-97
Published online Jul 27, 2014. doi: 10.5411/wji.v4.i2.88
Table 1 Review of animal pythiosis cases reported in the literature when treated with immunotherapy
Species/nLesionsAdjunctive therapyImmunotherapy type3, dosesOutcomeRef.
Horses
40Various4No or surgeryUF, 31 doses at 7-d intervalsC (53%), I (33%)[103]
5LimbsATM, surgeryUF, 3 doses at 7-d intervalsC (20%), 60(E), 20 (D)[60]
5Various4NoSA, 2 doses at 15-d intervalsC (60%)[88]
1Limb, bonesNoSA, 2 doses at 7-d intervalsE[109]
71Various4NrFH or SA, 1 or 2 doses at 7-d intervalsC (66%)[104]
1Limb, bonesSurgery, ATMNr, 3 doses postsurgicalD[110]
2AbdomenSurgery, ATMSH, 3 doses at 7-d intervalsC (50%), E (50%)[111]
19Various4NoLMH, 3 to 9 doses at 14-d intervalsC (50%-83%)[107]
18Various4Surgery, ATMSA + SH, 21 doses at 15-d intervalsC (72%)[17]
1Limbs, sub-maxillarySurgeryNrE[23]
1LimbATMLMH, 7 doses at 14-d intervalsD[112]
1Hind pastern, fetlockATBSA, 3 doses at 1, 7 and 21 dE[113]
1FaceSurgery, ATMLMH, 5 doses at 14-d intervalsE[114]
1FaceATMLMH, 5 doses at 14-d intervalsC[64]
12Limb, abdomenNoLMH, 4-5 doses at 14-d intervalsC[115]
11Limbs, abdomenNo or surgeryLMH, 2-5 doses at 14-d intervalsC (70%-90%)[24]
8Limbs, abdomenNo or surgeryLMH, NrC (75%)[7]
47Various4No or surgeryLMH, NrC (79%-84%)[9]
Dogs
1CutaneousAMB, surgeryUF, 1 doseC[38]
6Cutaneous, intestinalATM, surgerySA + SH, 21 doses at 15-d intervalsC (33%)[17]
2CutaneousItraconazoleSA, 1 or 2 doses at 7-d intervalsE[31]
1CutaneousNoSA, 2 doses at 14-d intervalsC[35]
1GastrointestinalATF, surgeryNr, 3 doses at 1, 7 and 21 dC[32]
1GastrointestinalATFSA, 6 doses at 15-d intervalsC[108]
Camels
1Face, stomachSurgery, ATMSA + SH, 21 doses at 14-d intervalsD[68]
2VulvarSurgery, ATMSA, 3 doses at 1, 10, 17 dC (50%)[21]
Sheep
6OronasalNoLMH, 1-5 doses at 14-d intervalsC (16.7%)[41]